How FDA's latest compounding guidance affects veterinarians - News - VIN
FDA's latest compounding guidance clarifies rules for veterinarians, potentially affecting drug sourcing and compounding practices. This may impact pharmaceutical manufacturers supplying animal drugs or compounding ingredients.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 28, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Compounding outsourcing facilities (503B) and API manufacturers supplying veterinary compounding should confirm how it applies to their specific situation before acting. There is a time constraint attached: Ongoing; compliance expected upon issuance.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
FDA issued new guidance on compounding for veterinarians, specifying conditions for lawful compounding from bulk drug substances and addressing office-use compounding.
Who it affects
Compounding outsourcing facilities (503B) and API manufacturers supplying veterinary compounding
What you must do
Review the guidance to ensure compounding practices and ingredient sourcing comply with new FDA expectations.
Deadline
Ongoing; compliance expected upon issuance.
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Court of Appeals Affirms Judgment that Struck Down Rule Mandating Price Disclosure in Pharmaceutical Ads - Holland & Knight
- Virginia Prepares to Accept Applications for a Single Medical Cannabis License for Health Service Area 1, Which Includes the Shenandoah Valley - Foley Hoag
- Glenmark suffers recall, warning letter after subpar investigation into tablet manufacturing glitch - Fierce Pharma
- February 17, 2026: Pennsylvania compounding pharmacy earns another FDA warning letter - Partnership for Safe Medicines
- Governor signs bill requiring informed consent for nursing home patients for prescription of antipsychotic drugs - Oklahoma State Senate (.gov)